As we are refreshing our thoughts on BioMerieux, we are reinstating our narrow moat rating. BioMerieux is a niche player in the fragmented in vitro diagnostic market and has specialty positioning in ...
BioMerieux’s strategy is threefold: maintain market leadership in the niche areas of microbiology and syndromic testing, continue to expand the market in diagnostics in syndromic testing, and ...